X0609 4 2026-09-01 0001842295 Maze Therapeutics, Inc. MAZE 0002050172 Bernstein Harold false C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 false true false false President, R&D & CMO 1 Common Stock 2026-09-01 4 M 0 16141 10.42 A 16141 D Common Stock 2026-09-01 4 S 0 16141 26.3622 D 0 D Common Stock 2026-09-01 4 M 0 20000 0 A 20000 D Stock Option (Right to Buy) 10.42 2026-09-01 4 M 0 16141 0 D 2032-10-26 Common Stock 16141 160662 D Restricted Stock Units 2026-09-01 4 M 0 20000 0 D Common Stock 20000 20000 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. /s/ Courtney Phillips, as attorney-in-fact 2026-09-03